ArriVent shares rise after snagging $175M in year’s second IPO

26 Jan 2024
ImmunotherapyIPOPhase 3
ArriVent posted modest gains during its first day of trading Friday, rising 11% to close at $20. The oncology company became the second biotech to make its public debut this year after raising $175 million in an IPO late Thursday.
ArriVent follows closely behind CG Oncology, which raised $380 million Wednesday in its massively upsized IPO and nearly doubled its share price during its first day of trading. For more, see Vital Signs: CG Oncology breaks into the top ten.
ArriVent’s offering, however, was mostly in-line with the terms it initially proposed on Monday. The company sold 9.7 million shares at $18, the midpoint of its range. The amount sold was slightly bumped-up from the originally proposed 8.3 million shares, giving ArriVent a market capitalisation of about $575 million.
Both newly public biotechs have Phase III cancer compounds. ArriVent’s lead asset furmonertinib is a tyrosine kinase inhibitor to treat first-line EGFR-mutant non-small-cell lung cancer with exon 20 insertion mutations. CG Oncology’s oncolytic immunotherapy cretostimogene grenadenorepvec is in development for high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.